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Abstract The cardiovascular safety profile of dapoxetine, a novel selective serotonin
reuptake inhibitor (SSRI) developed as an on-demand oral treatment for
premature ejaculation (PE) in men, is evaluated. The cardiovascular assess-
ment of dapoxetine was conducted throughout all stages of drug develop-
ment, with findings from preclinical safety pharmacology studies, phase I
clinical pharmacology studies investigating the effect of dapoxetine on
QT/corrected QT (QTc) intervals in healthy men, and phase III, randomized,
placebo-controlled studies evaluating the safety (and efficacy) of the drug.
Preclinical safety pharmacology studies did not suggest an adverse electro-
physiologic or hemodynamic effect with concentrations of dapoxetine up to
2-fold greater than recommended doses. Phase I clinical pharmacology
studies demonstrated that dapoxetine did not prolong the QT/QTc interval
and had neither clinically significant electrocardiographic effects nor evi-
dence of delayed repolarization or conduction effects, with dosing up to
4-fold greater than the maximum recommended dosage. Phase III clinical
studies of dapoxetine in men with PE indicated that dapoxetine was generally
safe and well tolerated with the dosing regimens used (30mg and 60mg as
required). Events of syncope were reported during the clinical development
program, with the majority occurring during study visits (on site) on day 1 fol-
lowing administration of the first dose when various procedures (e.g. orthostatic
maneuvers, venipunctures) were performed, suggesting that the procedures
contributed to the incidence of syncope. This was consistent with previous re-
ports showing that these and similar factors contribute to or trigger vasovagal
syncope. Findings of the dapoxetine development program demonstrate that
dapoxetine is associated with vasovagal-mediated (neurocardiogenic) syncope.
No other associated significant cardiovascular adverse events were identified.
1. Introduction
Premature ejaculation (PE) is a sexual dys-
function characterized by short intravaginal
ejaculatory latency time, an inability to control or
delay ejaculation, and negative personal conse-
quences such as distress, bother, or frustration.[1,2]
Although sexual activity has been identified
as a potential cardiac risk factor in patients
with pre-existing cardiovascular disease,[3] PE has
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not been associated with any cardiovascular co-
morbidities or health risks.[4]
Dapoxetine is a novel selective serotonin re-
uptake inhibitor (SSRI) developed as an on-
demand oral treatment for PE and has been granted
marketing authorization for the treatment of
PE in men aged 18–64 years in 15 countries (as
of August 2010).[5,6] The pharmacokinetics
of dapoxetine (e.g. maximum plasma concentra-
tion [Cmax] and elimination half-life) are time-
invariant, and increases are in a dose proportional
manner. The pharmacokinetics are unaffected by
age, ethnicity, or single or multiple dosing (30 and
60mg). Dapoxetine demonstrates rapid absorption
and elimination with minimal accumulation fol-
lowing daily dosing, and is extensively metabo-
lized by multiple enzymes.[7-9]
Other SSRI medications approved for the
treatment of depression have been shown to delay
ejaculation in patients being treated for depres-
sion[10,11] and are used as off-label treatment for
PE.[12,13] In comparison with dapoxetine, other
SSRI medications have relatively slower absorp-
tion, resulting in potentially longer periods of
exposure and accumulation. SSRIs approved for
the treatment of depression, anxiety, and other
psychiatric conditions have infrequently been
associated with reports of cardiovascular adverse
events (e.g. arrhythmias, orthostatic hypoten-
sion, syncope).[14-16] During premarketing clinical
studies for these medications, adverse events, such
as hypertension, tachycardia, and palpitations,
were reported as more frequent events.[17-19]
Here, we describe the evaluation of the cardio-
vascular safety of dapoxetine by Johnson &
Johnson Pharmaceutical Research & Develop-
ment, L.L.C.,[5] including the background and
rationale for studies at each phase of develop-
ment. The cardiovascular assessment of dapox-
etine was conducted throughout all stages of drug
development. Guidelines from health authorities
were followed when available.[20-23]
The key studies evaluating the cardiovas-
cular safety of dapoxetine included the follow-
ing: (i) preclinical safety pharmacology studies;
(ii) phase I clinical pharmacology studies investi-
gating the effect of dapoxetine onQT/corrected QT
(QTc) intervals in healthy men; and (iii) phase II
and III, randomized, placebo-controlled studies
evaluating the safety (and efficacy) profile of da-
poxetine. Here, we describe the findings from
these investigations that characterize the cardio-
vascular safety profile of dapoxetine.
2. Preclinical Safety Pharmacology
Studies
Preclinical safety pharmacology studies eval-
uated the pharmacodynamic effects of dapox-
etine on physiologic functions that may have
relevance to its safety in humans.[5] Key findings
from these studies,[5] with potential implications
for understanding the cardiovascular safety pro-
file of dapoxetine, are reviewed here. Dapoxetine
decreased membrane potassium current in the
human ether-a`-go-go related gene (hERG) trans-
fected human embryonic kidney cell line with a
50% inhibitory concentration (IC50) of 3.26 mM.
In man, the Cmax after a 60mg dose (the highest
therapeutic dose) is 427 ng/mL, equivalent to
dapoxetine 1.4 mmol/L in vitro. The ratio of the
expected Cmax in man to the IC50 is thus about
2.3, suggesting an acceptable therapeutic safety
margin of dapoxetine. Other electrophysiologic
effects included a significant decrease in the am-
plitude of the action potential in conditions of a
normal rhythm, and bradycardia in Purkinje fi-
bers isolated from laboratory rabbits exposed to
dapoxetine 10 mmol/L. These results indicate a
blockade of sodium and calcium currents with
high concentrations of dapoxetine in rabbit con-
duction tissue.
In the anesthetized guinea pig, there were no
significant changes in the duration of PQ, QRS,
or QTcB (corrected for heart rate) intervals
compared with baseline intervals at total intra-
venous doses of dapoxetine up to 9.87mg/kg,
yielding exposures as high as 4.0 mmol/L.[5] At a
total intravenous dose of 39.38mg/kg, dapox-
etine increased the PQ interval and the QRS in-
terval, but decreased the QTcB interval compared
with baseline. There were also dose-dependent
decreases in heart rate and increases in blood
pressure (BP) at this very high exposure. No ef-
fects on QTc interval were observed in anes-
thetized dog, conscious dog, or monkey studies.[5]
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In summary, preclinical safety pharmacology
studies suggested that adverse electrophysiologic
or hemodynamic effects are unlikely with con-
centrations of dapoxetine up to 2-fold greater
than recommended doses.
3. Phase I Clinical Pharmacology
QT Interval Studies
Regulatory guidelines ensure the clinical eval-
uation of QT/QTc interval prolongation and
proarrhythmic potential for new drugs with sys-
temic bioavailability.[20,23] Based on these guide-
lines, several studies were performed to evaluate
the effect of a range of single oral doses of da-
poxetine on QT/QTc interval. Two studies were
conducted in healthy adult male subjects (n = 336)
with dapoxetine 60, 120, and 240mg, placebo,
and oral moxifloxacin 400mg as a positive con-
trol to demonstrate assay sensitivity.[24]
In these studies, dapoxetine at doses up to
4-fold greater than the maximum recommended
dose did not prolong the QT/QTc interval com-
pared with placebo and had no clinically signif-
icant electrocardiographic effects. Moxifloxacin
significantly increased QT and QTc intervals
compared with placebo in both studies. These
findings were consistent across all the correction
methods used, while there was no dose response
in the QT/QTc effect. At clinically relevant ex-
posures, dapoxetine demonstrated no evidence of
delayed repolarization or conduction effects.[24]
In the QT/QTc interval studies, most adverse
events were of mild severity and no serious adverse
events were reported. There was a single report of
vasovagal syncope, which occurred 2 hours after
the first dapoxetine dose at the time of the postdose
blood collection. In the other 21 phase I studies,
four cases of syncope were reported.
4. Phase II, Randomized, Placebo-
Controlled Studies
Two phase II studies evaluated the safety and
efficacy of a range of doses of dapoxetine
(20–100mg) in multicenter, placebo-controlled
trials in healthy adult men with PE. Dapoxetine
treatment was generally safe and well tolerated
across the range of doses, with no notable car-
diovascular-related safety events directly attrib-
uted to dapoxetine treatment.[25] However, there
was a pattern of higher overall adverse event in-
cidence with dapoxetine 100mg compared with
dapoxetine 60mg and placebo. The most common
adverse events were nausea, dizziness, diarrhea,
insomnia, headache, and nervousness. Adverse
events occurred predominantly with the first dose
of dapoxetine study drug administered, were grad-
ed as mild to moderate in severity, and judged to be
treatment-related by the investigators. There were
no clinically relevant mean changes in ECG or vital
sign data.
5. Phase III, Randomized, Placebo-
Controlled Studies
The cardiovascular safety analyses were per-
formed in five phase III clinical studies that as-
sessed the overall efficacy and safety of dapoxetine
in 6081 men with PE.[6,26-30] These multicenter,
randomized, placebo-controlled studies were con-
ducted with 30 and 60mg doses of dapoxetine.
Four of the five placebo-controlled studies were
conducted with the proposed dapoxetine dosing
regimens (30 or 60mg as required),[26,28-30] where-
as one placebo-controlled study was conducted
with dapoxetine 60mg as required or 60mg once
daily.[27] The phase III clinical studies are regis-
tered at ClinicalTrials.gov as NCT00229073,[26]
NCT00210613,[27]NCT00210704,[28]NCT00211107,[29]
and NCT00211094.[29]
Overall, dapoxetine treatment was generally
safe and well tolerated with the tested dosing reg-
imens. The safety profile of dapoxetine was gen-
erally consistent across the clinical studies, with
the adverse effects consistent with the SSRI class
of drugs, although the incidence and severity varied.
The most common adverse events were those asso-
ciated with the gastrointestinal and nervous system
organ classes, and reflected acute symptomatic
events that were generally self-limiting and tempo-
rally related to dosing, reflecting tolerability rather
than serious safety concerns.[26-30]
Special attention was given to cardiovascular-
related safety issues since syncope has been re-
ported with marketed SSRIs[14-16] and there were
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five cases of vasovagal syncope during dapox-
etine phase I studies. During the initial two phase
III clinical studies of dapoxetine, further cases of
syncope were reported although, at the time, the
occurrence appeared balanced among the place-
bo, 30mg, and 60mg treatment groups (2 of 872
[0.2%], 3 of 876 [0.3%], and 2 of 870 [0.2%] epi-
sodes, respectively). Holter monitoring and or-
thostatic maneuvers were implemented in later
phase III studies to enhance detection of syncopal
and presyncopal events, and to ensure that the
clinical database contained relevant and robust
information regarding the circumstances of the
occurrence of syncope.[26-28]
Treatment-emergent adverse events associated
with the cardiovascular system were evaluated
from the pooled data from the five phase III
studies (n = 6081).[26-30] Table I provides the over-
all incidence and the adverse events reported in
five or more dapoxetine-treated subjects. The
overall incidence of cardiovascular adverse events
appeared to be dose related, occurring in 5.2%
of patients receiving placebo, 7.7% receiving
dapoxetine 30mg as required, 16% receiving
60mg as required, and 24.5% receiving 60mg
once daily. The most common adverse event was
dizziness, occurring in 2.2%, 5.8%, 10.9%, and
14.9% of patients, respectively. Cardiovascular
etiology is not the only cause for dizziness, and
the rates of cardiovascular adverse events ex-
cluding dizziness were 3.4%, 2.2%, 6.3%, and
12.2%, respectively. Orthostatic hypotension
was also seen in 1.3% of dapoxetine-treated sub-
jects. Other cardiovascular-related adverse events
were reported rarely with an overall frequency of
<1%. Sixteen cases of syncope, ten coding to the
preferred term ‘syncope’ and six as ‘vasovagal
syncope’ in theMedical Dictionary for Regulatory
Activities (MedDRA), were reported in the five
phase III studies. In placebo- and dapoxetine-
treated groups, the respective incidence was
0.11% and 0.19% for syncope, and 0.05% and
0.12% for vasovagal syncope, indicating a rela-
tive risk of about 2 with dapoxetine. These events
Table I. Cardiovascular adverse events occurring in five or more dapoxetine-treated subjects in five phase III placebo-controlled studies
Cardiovascular adverse
eventsa










Total with a cardiovascular
adverse event
97 (5.2) 125 (7.7) 338 (16.0) 123 (24.5) 586 (13.9)
Total excluding dizziness 63 (3.4) 36 (2.2) 133 (6.3) 61 (12.2) 230 (5.4)
Preferred term
dizziness 40 (2.2) 94 (5.8) 230 (10.9) 75 (14.9) 399 (9.4)
orthostatic hypotension 13 (0.7) 6 (0.4) 26 (1.2) 24 (4.8) 56 (1.3)
blood pressure increased 3 (0.2) 7 (0.4) 19 (0.9) 7 (1.4) 33 (0.8)
palpitations 5 (0.3) 3 (0.2) 23 (1.1) 0 26 (0.6)
blood pressure orthostatic 8 (0.4) 0 12 (0.6) 11 (2.2) 23 (0.5)
hypertension 16 (0.9) 3 (0.2) 11 (0.5) 9 (1.8) 23 (0.5)
heart rate increased 2 (0.1) 2 (0.1) 10 (0.5) 3 (0.6) 15 (0.4)
tachycardia 3 (0.2) 5 (0.3) 9 (0.4) 0 14 (0.3)
syncope 2 (0.1) 0 6 (0.3) 2 (0.4) 8 (0.2)
hypotension 0 0 5 (0.2) 1 (0.2) 6 (0.1)
blood pressure orthostatic
increased
0 0 3 (0.1) 2 (0.4) 5 (0.1)
syncope vasovagal 1 (0.1) 2 (0.1) 3 (0.1) 0 5 (0.1)
a Adverse events were summarized using theMedical Dictionary for Regulatory Activities (MedDRA), terminology. Counts (%) are based on
the number of subjects, not the number of events. Results include five phase III studies.[26-30]
od =once daily; prn = as required.
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were further evaluated as part of a comprehensive
assessment of syncope as described in section 6.
5.1 Holter Monitoring
In three phase III studies, Holter ECG mon-
itoring was performed on all subjects, beginning
10–30 minutes before and ending 3 hours after
the first dose of study drug.[26-28] The timing of
Holter monitoring captured the time of expected
dapoxetine peak concentrations, 1–3 hours fol-
lowing oral administration of doses in the range
of 30–60mg.[8] Subjects remained within the clinic
during this time under direct supervision to mon-
itor for any untoward events. Pooled Holter mon-
itoring data from the three studies were evaluated
for total incidence of abnormalities and number of
events per hour during monitoring.
Table II summarizes the incidence of Holter
monitoring abnormalities around the time of first
dose in these three phase III studies.[26-28] In 3353
patients, no symptomatic or sustained (continuous)
tachyarrhythmias were detected. The incidence of
Holter-detected non-sustained ventricular tachy-
cardia was similar between dapoxetine-treated
subjects and those who received placebo, suggesting
that dapoxetine is not arrhythmogenic and that ta-
chyarrhythmia is thus unlikely to be the underlying
mechanism responsible for syncope seen in the da-
poxetine clinical program. There was a statistically
nonsignificant increase in the number of single ven-
tricular and supraventricular ectopic beats in the
dapoxetine groups, but this finding is not considered
clinically meaningful, given the generally benign
nature of ventricular ectopic beats occurring on their
own in the absence of structural heart disease.[31]
5.2 Orthostatic Measurements
Orthostatic vital sign measurements were per-
formed in three phase III studies on the first day
of dosing to evaluate whether orthostatic hypo-
tension could potentially play a role in the occur-
rence of syncope in dapoxetine recipients.[26-28]
Orthostatic hypotension was defined according
to guidelines provided by the National Institutes
of Health (NIH) in the Joint National Committee
for Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure (JNC-7) proceed-
ings.[32] Orthostatic hypotension was considered
present with a supine to standing BP decrease of
>20mmHg systolic or >10mmHg diastolic.
The number and percentage of subjects with
orthostatic hypotension, shifts from baseline, and
outliers at the time of first dose are summarized in
table III. There were small differences with or-
thostatic hypotension and orthostatic systolic BP
after dosing on the first day, but these were not
statistically different across the groups. Shift anal-
ysis for orthostatic hypotension and BP com-
paring pre- and post-dose incidence after dosing
on the first day showed no notable or consistent
differences between the placebo and dapoxetine
groups. Additionally, evaluation of orthostatic
BP changes after dosing by category/limits of
change showed that the majority of subjects in
all treatment groups had diastolic BP changes
£10mmHg and systolic BP changes of £20mmHg,
with no significant differences between the pla-
cebo and dapoxetine groups. These results in-
dicated no evidence of an effect of dapoxetine on
orthostatic blood pressure.
6. Program-Wide Evaluation of Syncopal
Events
In response to the observation of cases of
syncope in the development program for dapox-
etine, a program-wide process was established to
identify all cases of syncope and related events. A
search of the dapoxetine clinical database for all
verbatim terms and MedDRA preferred terms
(such as syncope, presyncope, or feeling faint)
identified 37 cases of interest. A treatment-
blinded committee of external experts in cardio-
vascular medicine, after review of blinded patient
narratives, adjudicated whether a case of interest
represented a true syncopal event per the medical
definition of ‘‘a sudden loss of consciousness
associated with the inability to maintain postural
tone, followed by spontaneous recovery.’’[33]
Additional data were collected to evaluate the
incidence, temporal relationship to dosing, etio-
logy, and sequelae of these syncope events.
All adjudicated syncope cases and cases of in-
terest were evaluated by treatment group and
drug exposure in phases I through to III of the
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clinical program. The highest incidence of syn-
copal events was reported in the phase I studies,
and this was considered likely to be due to study-
related precipitating factors (e.g. venipuncture).
Incidence during phase I–III studies was sum-
marized by whether the event occurred predose
or after the administration of blinded study drug
(table IV), and whether the event occurred with
the first or subsequent dose, and with on-site or
off-site dosing (table V). A dose-response rela-
tionship for syncope is suggested based on subject
incidence across all studies, and the results sug-
gested that on-site (compared with off-site) drug
administration and initial (compared with sub-
sequent) dosing on day 1 were associated with
an increased incidence of syncope, although dif-
ferences were not statistically significant. In
phase III studies, various on-site procedures on
day 1, such as vital sign measurements, orthostatic
maneuvers and ECG/Holter recordings, were per-
formed and these procedures may have con-
tributed to the higher on-site incidence of syncope.
Based on the judgment of the adjudication
committee, the percentage of subjects with syn-
Table II. Incidence of Holter monitoring abnormalities at the time of first dose in three phase III studies








single 205 (21.6) [19, 24.33] 162 (22.7) [19.64, 25.91] 408 (24.2) [22.14, 26.29]
couplets 15 (1.6) [0.89, 2.59] 13 (1.8) [0.97, 3.09] 28 (1.7) [1.1, 2.39]
ventricular runsc 5 (0.5) [0.17, 1.22] 3 (0.4) [0.09, 1.22] 8 (0.5) [0.2, 0.93]
ventricular tachycardiad 2 (0.2) [0.03, 0.76] 2 (0.3) [0.03, 1] 5 (0.3) [0.1, 0.69]
Supraventricular ectopy
single 389 (40.9) [37.8, 44.15] 307 (42.9) [39.27, 46.66] 810 (48) [45.58, 50.4]
couplets 32 (3.4) [2.32, 4.72] 34 (4.8) [3.32, 6.58] 92 (5.5) [4.42, 6.64]
supraventricular runsc 22 (2.3) [1.46, 3.49] 18 (2.5) [1.5, 3.95] 49 (2.9) [2.16, 3.82]
Heart rate
maximum heart rate >130bpm 75 (7.9) [6.26, 9.8] 55 (7.7) [5.85, 9.9] 70 (4.1) [3.25, 5.21]
minimum heart rate <40 bpm 20 (2.1) [1.29, 3.23] 12 (1.7) [0.87, 2.91] 31 (1.8) [1.25, 2.6]
RR interval
longest RR interval >2 sec 17 (1.8) [1.05, 2.85] 18 (2.5) [1.5, 3.95] 21 (1.2) [0.77, 1.9]
AV block
1st degree (pulse rate >200msec) 12 (1.2) [0.65, 2.17] 12 (1.7) [0.86, 2.87] 23 (1.3) [0.85, 2.01]
2nd degree (type I) 2 (0.2) [0.03, 0.76] 0 1 (0.1) [0, 0.33]
2nd degree (type II) 0 0 0
Conduction abnormalities
RBBB 7 (0.7) [0.3, 1.51] 8 (1.1) [0.48, 2.19] 8 (0.5) [0.2, 0.93]
LBBB 1 (0.1) [0, 0.59] 0 1 (0.1) [0, 0.33]
IVCD 0 0 1 (0.1) [0, 0.33]
Atrial fibrillation 3 (0.3) [0.07, 0.92] 6 (0.8) [0.31, 1.8] 7 (0.4) [0.17, 0.85]
Atrial flutter 0 0 0
a Incidence is based on the number of subjects experiencing each event. Each subject is counted only once in each category, regardless of
number of events in the subject. Results include three phase III studies.[26-28]
b Two-sided 95% confidence intervals using exact confidence interval method.
c ‡3 consecutive beats.
d ‡3 consecutive ventricular beats, ‡100bpm.
AV = atrioventricular; bpm =beats per minute; IVCD = interventricular conduction defect; LBBB = left bundle branch block; RBBB = right
bundle branch block.
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cope resulting in loss of consciousness in the
phase III placebo-controlled studies was low and
dose related, but was similar for the placebo (1 of
1857 [0.05%]) and dapoxetine 30mg (1 of 1616
[0.06%]) groups, although higher in the dapox-
etine 60mg group (6 of 2608 [0.23%]).
Simple modifiable risk factors, such as ade-
quate hydration and implementation of preven-
tion maneuvers, can effectively minimize syncope
occurrence.[34,35] In order to reduce the likelihood
of syncope occurrence in the late phase of the
dapoxetine development program, patient in-
structions were introduced into the then-ongoing
phase I and III clinical studies to educate patients
regarding the possibility of prodromal symptoms
and to provide instruction on appropriate actions
to be taken in order to prevent progression of
such symptoms to actual loss of consciousness.
No new cases of syncope were reported in the
1175 subjects who received dapoxetine treatment
(of which 367 were newly randomized and re-
ceived their first dose) after the implementation
of these instructions and removal of orthostatic
maneuvers from the study designs.
Table III. Incidence of orthostatic hypotension (JNC-7 criteriaa), shifts from baseline, and outliers at the time of first dose in three phase III
studies
Measurementb Treatment group {n/N (%) [95% CI]c}
placebo dapoxetine 30mg dapoxetine 60mg
Orthostatic hypotensiona
Baseline 12/819 (1.5) [0.76, 2.55] 11/571 (1.9) [0.97, 3.42] 40/1566 (2.6) [1.83, 3.46]
Day 1 (postdose) 71/821 (8.6) [6.82, 10.78] 55/577 (9.5) [7.26, 12.23] 163/1565 (10.4) [8.95, 12.04]
Shift from baselined 68/815 (8.3) [6.54, 10.46] 48/566 (8.5) [6.32, 11.09] 148/1556 (9.5) [8.1, 11.08]
Orthostatic diastolic blood pressurea
Baseline 9/819 (1.1) [0.5, 2.08] 5/571 (0.9) [0.28, 2.03] 25/1566 (1.6) [1.04, 2.35]
Day 1 (postdose) 48/821 (5.8) [4.34, 7.68] 32/577 (5.5) [3.82, 7.74] 93/1565 (5.9) [4.82, 7.23]
Shift from baselined 47/815 (5.8) [4.27, 7.6] 30/566 (5.3) [3.6, 7.48] 83/1556 (5.3) [4.27, 6.57]
Change in diastolic blood pressuree
‡ -10 774/822 (94.2) [92.33, 95.66] 549/581 (94.5) [92.31, 96.2] 1481/1574 (94.1) [92.81, 95.2]
-20 to -10 41/822 (5) [3.6, 6.71] 26/581 (4.5) [2.94, 6.49] 87/1574 (5.5) [4.45, 6.77]
-30 to -20 6/822 (0.7) [0.27, 1.58] 5/581 (0.9) [0.28, 2] 5/1574 (0.3) [0.1, 0.74]
-50 to -30 1/822 (0.1) [0, 0.68] 1/581 (0.2) [0, 0.96] 1/1574 (0.1) [0, 0.35]
Orthostatic systolic blood pressurea
Baseline 5/820 (0.6) [0.2, 1.42] 8/571 (1.4) [0.61, 2.74] 19/1566 (1.2) [0.73, 1.89]
Day 1 (postdose) 32/821 (3.9) [2.68, 5.46] 28/577 (4.9) [3.25, 6.94] 91/1565 (5.8) [4.71, 7.09]
Shift from baselined 32/816 (3.9) [2.7, 5.49] 24/566 (4.2) [2.74, 6.24] 86/1556 (5.5) [4.44, 6.78]
Change in systolic blood pressuree
‡ -20 790/822 (96.1) [94.55, 97.32] 553/581 (95.2) [93.11, 96.77] 1483/1574 (94.2) [92.95, 95.32]
-30 to -20 27/822 (3.3) [2.18, 4.74] 23/581 (4) [2.53, 5.88] 81/1574 (5.1) [4.11, 6.36]
-40 to -30 3/822 (0.4) [0.08, 1.06] 3/581 (0.5) [0.11, 1.5] 9/1574 (0.6) [0.26, 1.08]
-50 to -40 1/822 (0.1) [0, 0.68] 1/581 (0.2) [0, 0.96] 0/1574 (0) [0, 0.23]
-70 to -50 1/822 (0.1) [0, 0.68] 1/581 (0.2) [0, 0.96] 1/1574 (0.1) [0, 0.35]
a Orthostatic hypotension defined by the Joint National Committee for Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC-7) criteria as a supine to standing blood pressure decrease of >20mmHg systolic or >10mmHg diastolic.
b Baseline measurement was 15 minutes predose; postdose measurement was anytime at 1, 1.5, 2, and 3 hours postdose. Results include
three phase III studies.[26-28]
c Two-sided 95% confidence intervals using exact confidence interval method.
d Subjects who met JNC-7 criteria at day 1 postdose but not at baseline.
e Change in blood pressure (mmHg) from supine to standing at day 1 postdose.
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7. Discussion
The stages of drug development from pre-
clinical through to pivotal clinical studies provide
information to characterize the cardiovascular
safety of a new drug, while relevant findings from
one phase may be reason to modify or expand
subsequent research to evaluate certain findings.
A potential signal detected during the preclinical
and clinical development process may merit fur-
ther investigation to establish and characterize
the relevance of these findings. Although the
analysis typically occurs in a sequential fashion,
in line with the traditional stages of drug devel-
opment, the final assessment of the cardiovascu-
lar safety of a drug requires an integration and
synthesis of all information garnered throughout
the research and development programs.
The cardiovascular safety profile of dapox-
etine was investigated during the premarketing
evaluation of the medication. Dapoxetine is an
SSRI and, as a new compound in this class, it
merited special attention, given that other SSRI
medications approved for the treatment of de-
pression, anxiety, and other psychiatric con-
ditions have infrequently been associated with
reports of cardiovascular adverse events.[14-16] It
was also important to assess the cardiovascular
safety profile of dapoxetine because the proposed
indication (i.e. PE) is not a life-threatening con-
dition, and so syncope, albeit rare, might offset
the clinical benefit.
The findings of preclinical safety pharmacol-
ogy studies suggested that adverse electrophysio-
logic or hemodynamic effects are unlikely at the
concentrations of dapoxetine achieved with rec-
ommended doses (section 2). Phase I clinical
pharmacology studies showed that dapoxetine
did not prolong the QT/QTc interval and had no
clinically significant electrocardiographic effects,
with no evidence of delayed repolarization or
conduction effects (section 3). Phase III clinical
studies of dapoxetine in men with PE indicated
that dapoxetine treatment was generally safe and
well tolerated with the recommended dosing
regimens of 30 and 60mg as required (section 5).
Extensive analyses were conducted to inves-
tigate the etiology and factors predisposing to the
occurrence of syncope in the dapoxetine clinical
program (section 6). It was noted that the ma-
jority of syncopal events across the entire da-
poxetine program occurred during study visits
(on site) on day 1 following administration of the
first dose when various study-related procedures,
Table IV. Subjects with syncope before (predose) and after administration of dapoxetine by dose group in phase I–III dapoxetine studies
Syncope cases by treatment Subjects treated (N) Subjects with event {n (%) [95% CI]a}
Adjudicated syncopeb
Predose 7219 2 (0.03) [0, 0.1]
Postdose
placebo 2435 1 (0.04) [0, 0.23]
dapoxetine 30mg 1944 2 (0.1) [0.01, 0.37]
dapoxetine 60mg 4636 11 (0.24) [0.12, 0.42]
other 610 2 (0.33) [0.04, 1.18]
Cases of interestc
Predose 7219 5 (0.07) [0.02, 0.16]
Postdose
placebo 2435 2 (0.08) [0.01, 0.3]
dapoxetine 30mg 1944 7 (0.36) [0.14, 0.74]
dapoxetine 60mg 4636 21 (0.45) [0.28, 0.69]
other 610 2 (0.33) [0.04, 1.18]
a Two-sided 95% confidence intervals using exact confidence interval method.
b Cases adjudicated with medical definition of syncope by a blinded committee of external experts.
c Adverse events identified in the dapoxetine clinical database that might reflect a syncope event.
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such as vital signs measurements, orthostatic
maneuvers, ECG/Holter recordings (in phase III
studies), and venipunctures (in phase I studies)
were performed. These procedures may have
contributed to the incidence of syncope, as these
and similar factors are known to contribute to or
trigger vasovagal syncope.[36-39]
Serotonin mediates BP control through both
afferent and efferent serotonergic pathways, and
alteration of serotonergic pathways can provoke
or prevent a vasovagal response.[37,40,41] The
principal action that leads to hypotension and
bradycardia in neurocardiogenic syncope ap-
pears to be sudden and profound sympathetic
withdrawal.[41] In a tilt-testing study in humans,
clomipramine, which has serotonin reuptake in-
hibitory activity, was found to provoke such a
vasovagal response, suggesting a role of seroto-
nin in cardiac regulation.[42] A similar form of
sympathetic withdrawal has been reported in an
animal model following injection of serotonin
into the intracerebral ventricular areas, suggest-
ing that acute changes in serotonin may act at a
central level to inhibit sympathetic activity, and
that the vasodilatation and bradycardia seen
during neurocardiogenic syncope may have a
central serotonergic component.[43] Thus, agents
that influence serotonergic activity may contrib-
ute to a vasovagal response, indicating that a
vasovagal (neurocardiogenic) mechanism ap-
pears to be the most likely etiology of syncope
reported in the dapoxetine development.
An extensive assessment of dapoxetine did not
reveal any other significant cardiovascular ad-
verse events, although such events have been as-
sociated with other antidepressant SSRIs. For
instance, prescribing information for antidepres-
sant SSRIs report that during premarketing
clinical studies, adverse events such as hyperten-
sion, tachycardia, palpitations, and chest pain
were observed frequently.[17-19] This pattern of
findings suggests that cardiovascular safety issues
may not be generalizable across the SSRI class
of drugs, and one reason for this may relate to
differences between each of the SSRI’s phar-
macokinetic characteristics.[17-19] Dapoxetine
demonstrates rapid absorption and elimination,
reaching Cmax within 1.5 hours of administration,
plasma concentrations are less than 5% of peak
at 24 hours, and there is minimal accumula-
tion following daily dosing.[7-9] In comparison,
other SSRI medications have relatively slower
absorption, and lack the rapid initial elimination
phase that is a characteristic of dapoxetine, re-
sulting in potentially longer periods of exposure
and accumulation.[8,24,44,45]
The premarketing evaluation of dapoxetine
provided a comprehensive assessment of the
cardiovascular safety of dapoxetine. However,
there are potential limitations on the sensitivity of
the premarketing studies related to study design,
such as the number of subjects treated and the du-
ration of treatment. In addition, the premarketing
findings are limited due to the lack of long-term
safety data on cardiovascular endpoints, such as
myocardial infarction, death, revascularization,
as well as surrogate endpoints, such as inflamma-
tion and platelet aggregation. The dapoxetine
Table V. Subjects with syncope at first or subsequent doses and at on-site or off-site dosing in phase I–III dapoxetine studies
Syncope cases by dosing On-site dosing Off-site dosing
subjects treated (N) subjects with event
{n (%) [95% CI]a}
subjects treated (N) subjects with event
{n (%) [95% CI]a}
Adjudicated syncopeb
First dose 3568 10 (0.28) [0.135, 0.515] 2171 1 (0.046) [0.001, 0.256]
Subsequent dose 557 1 (0.18) [0.005, 0.996] 4686 3 (0.06) [0.013, 0.187]
Cases of interestc
First dose 3566 15 (0.42) [0.236, 0.693] 2171 1 (0.046) [0.001, 0.256]
Subsequent dose 557 9 (1.62) [0.741, 3.045] 4686 5 (0.11) [0.035, 0.249]
a Two-sided 95% confidence intervals using exact confidence interval method.
b Cases adjudicated with medical definition of syncope by a blinded committee of external experts.
c Adverse events identified in the dapoxetine clinical database that might reflect a syncope event.
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research and development program includes on-
going long-term postmarketing and phase III
clinical studies, and so our understanding of the
cardiovascular safety of dapoxetine will continue
to evolve with the integration and synthesis of
relevant new information.
In conclusion, findings of the dapoxetine de-
velopment program indicate no associated sig-
nificant cardiovascular adverse events, except for
vasovagal-mediated (neurocardiogenic) syncope.
The incidence of syncope, albeit rare, should be
considered as part of the benefit/risk analysis
with the proposed indication (i.e. PE).
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